The Antibiotic Polymyxin B Modulates P2X7 Receptor Function1

The natural peptide polymyxin B (PMB) is a well-known and potent antibiotic that binds and neutralizes bacterial endotoxin (LPS), thus preventing its noxious effects among LPS-mediated endotoxin shock in animal models. We have investigated the effect of PMB on responses mediated by the P2X7R in HEK293 and K562 cells transfected with P2X7 cDNA and in mouse and human macrophages. In addition, in view of the potential exploitation of P2X7-directed agonists in antitumor therapy, we also investigated the effect of PMB in B lymphocytes from patients affected by chronic lymphocytic leukemia. PMB, at an optimal concentration dependent on the given cell type, greatly potentiated the effect of nucleotide-mediated P2X7 stimulation. In particular, ATP-mediated Ca2+ influx, plasma membrane permeabilization, and cytotoxicity were enhanced to an extent that, in the presence of PMB, cells were killed by otherwise ineffective nucleotide concentrations. The synergistic effect due to the combined application of ATP and PMB was prevented by incubation with the irreversible P2X blocker oxidized ATP (oATP), but not with the reversible antagonist 1-(N,O-bis(1,5-isoquinolinesulfonyl)-N-methyl-l-tyrosyl)-4-phenilpiperazine (KN-62). Cells lacking P2X7 were fully insensitive to the combined stimulation with PMB and ATP. Furthermore, PMB at the concentrations used had no untoward effects on cell viability. These results point to PMB as a useful tool for the modulation of P2X7R function and suggest that care should be used in the evaluation of ATP-stimulated immune cell responses in the presence of PMB as they may not solely be affected by removal of contaminating LPS.

[1]  U. Frey,et al.  1513A/C polymorphism in the P2X7 receptor gene in chronic lymphocytic leukemia: absence of correlation with clinical outcome , 2004, European journal of haematology.

[2]  G. Dubyak,et al.  Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptor‐independent mechanisms , 2003, British journal of pharmacology.

[3]  Guy Pratt,et al.  The P2X7 receptor gene polymorphism 1513 A→C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl‐2 family protein expression or survival in B‐cell chronic lymphocytic leukaemia , 2003, British journal of haematology.

[4]  F. Di Virgilio.  Novel data point to a broader mechanism of action of oxidized ATP: the P2X7 receptor is not the only target , 2003, British journal of pharmacology.

[5]  F. Di Virgilio,et al.  Tyrosine Phosphorylation of HSP90 within the P2X7 Receptor Complex Negatively Regulates P2X7 Receptors* , 2003, Journal of Biological Chemistry.

[6]  D. Oscier,et al.  P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12 , 2003, Leukemia.

[7]  F. Di Virgilio,et al.  Extracellular ATP causes ROCK I-dependent bleb formation in P2X7-transfected HEK293 cells. , 2003, Molecular biology of the cell.

[8]  A. Gewirtz,et al.  Secretion of IL-2 and IFN-γ, But Not IL-4, by Antigen-Specific T Cells Requires Extracellular ATP1 , 2003, The Journal of Immunology.

[9]  F. Di Virgilio,et al.  Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor. , 2003, Journal of medicinal chemistry.

[10]  L. Padyukov,et al.  Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia , 2002, The Lancet.

[11]  R. North,et al.  Epithelial Membrane Proteins Induce Membrane Blebbing and Interact with the P2X7 Receptor C Terminus* , 2002, The Journal of Biological Chemistry.

[12]  C. Gabel,et al.  Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response , 2002, The Journal of Immunology.

[13]  J. Wiley,et al.  A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study , 2002, The Lancet.

[14]  F. Di Virgilio,et al.  P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. , 2002, Blood.

[15]  R. North.  Molecular physiology of P2X receptors. , 2002, Physiological reviews.

[16]  Miran Kim,et al.  Proteomic and functional evidence for a P2X7 receptor signalling complex , 2001, The EMBO journal.

[17]  R. Hancock,et al.  Cationic peptides: effectors in innate immunity and novel antimicrobials. , 2001, The Lancet. Infectious diseases.

[18]  G. Dubyak,et al.  Cutting Edge: The Nucleotide Receptor P2X7 Contains Multiple Protein- and Lipid-Interaction Motifs Including a Potential Binding Site for Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.

[19]  F. Di Virgilio,et al.  Nucleotide receptors: an emerging family of regulatory molecules in blood cells. , 2001, Blood.

[20]  D. Bamford,et al.  Stages of Polymyxin B Interaction with theEscherichia coli Cell Envelope , 2000, Antimicrobial Agents and Chemotherapy.

[21]  M. Fridkin,et al.  The functional association of polymyxin B with bacterial lipopolysaccharide is stereospecific: studies on polymyxin B nonapeptide. , 2000, Biochemistry.

[22]  Kazuhide Inoue,et al.  Extracellular ATP Triggers Tumor Necrosis Factor‐α Release from Rat Microglia , 2000 .

[23]  F. Di Virgilio,et al.  Human primary fibroblasts in vitro express a purinergic P2X7 receptor coupled to ion fluxes, microvesicle formation and IL-6 release. , 1999, Journal of cell science.

[24]  F. Di Virgilio,et al.  Tenidap enhances P2Z/P2X7 receptor signalling in macrophages. , 1998, European journal of pharmacology.

[25]  D. Ferrari,et al.  Extracellular ATP Activates Transcription Factor NF-κB through the P2Z Purinoreceptor by Selectively Targeting NF-κB p65 (RelA) , 1997, The Journal of cell biology.

[26]  Manuel Buttini,et al.  Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram , 1997, British journal of pharmacology.

[27]  F. Di Virgilio,et al.  Extracellular ATP triggers IL-1 beta release by activating the purinergic P2Z receptor of human macrophages. , 1997, Journal of immunology.

[28]  C. Gargett,et al.  The isoquinoline derivative KN‐62 a potent antagonist of the P2Z‐receptor of human lymphocytes , 1997, British journal of pharmacology.

[29]  S. Lewis,et al.  Effects of Polymyxin B on Mammalian Urinary Bladder , 1996, The Journal of Membrane Biology.

[30]  E. Kawashima,et al.  The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7) , 1996, Science.

[31]  J. Corbett,et al.  Regulation of Inducible Nitric Oxide Synthase Expression by Macrophage Purinoreceptors and Calcium (*) , 1996, The Journal of Biological Chemistry.

[32]  R. North,et al.  Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors). , 1995, Molecular pharmacology.

[33]  F. Di Virgilio,et al.  The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. , 1995, The Journal of clinical investigation.

[34]  G. Dubyak,et al.  Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. , 1993, The American journal of physiology.

[35]  F. Di Virgilio,et al.  Oxidized ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. , 1993, The Journal of biological chemistry.

[36]  F. Di Virgilio.  The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. , 1995, Immunology today.